Upon binding to tumor-infiltrating CD8+ T cells (Arlauckas et al., 2017), it interferes with PD-1 binding to its ligands PD-L1 and PD-L2, expressed by tumor cells or antigen-presenting cells, including dendritic cells (DCs) (Garris et al., 2018; Oh et al., 2020; Peng et al., 2020; Waldman et al., 2020). The gene discussed is CD8A; the disease is neoplasm.